Dingell Hearings On Science Fraud: More Overkill Than Oversight

As chairman of the House Energy and Commerce Committee, which oversees the NIH, and its subcommittee on oversight and investigations, Rep. John Dingell (D-Mich.) has been investigating scientific fraud for over a year. No one questions the subcommittee's legitimate role of investigating fraud and ensuring that public funds are wisely spent. But many object to Dingell's unfair conduct and heavy-handed tactics. The subcommittee seems to have overstepped its mission as a watchdog of public funds. T

Written byEugene Garfield
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The subcommittee seems to have overstepped its mission as a watchdog of public funds. The recent hearings, held in May, leave the impression that Dingell is presiding over a kangaroo court, not a congressional inquiry.

The Dingell subcommittee has focused specifically on a disputed 1986 paper published in Cell (vol. 45, pages 247-259) and coauthored by David Baltimore, a Nobel laureate. Two university reviews and an official NIH investigation of the paper agree that certain data were misinterpreted but not intentionally misrepresented. All agree that the paper is an example of scientific error, not fraud.

This important distinction is lost on Dingell. At the May hearings, Dingell stressed his interest in preventing the waste of taxpayers' money on "faked" research. He has implied that a composite autoradiograph in the paper was a "fabrication," despite the authors' explanation that composites are commonly used.

Dingell's obvious bias has alarmed scientists and his ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies